1. Medtech Insight
  2. >>Business

Nexstim Looks To Break Into US TMS Market With Depression Indication

 
• By Reed Miller

The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.

Nestim NBT System
Nexstim's NBT System • Source: Nexstim PLC

Nexstim PLC has filed a 510(k) to US FDA for its NBT (Navigated Brain Therapy) transcranial magnetic stimulation (TMS) therapy system to be cleared for treating major depressive disorder.

Major depressive disorder is a chronic condition affecting 2%-5% of the population in developed countries

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D